PMID- 31955620
OWN - NLM
STAT- MEDLINE
DCOM- 20210121
LR  - 20210121
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 19
IP  - 5
DP  - 2020 May
TI  - Risk of adverse events in lymphoma patients treated with brentuximab vedotin: a 
      systematic review and meta-analysis.
PG  - 617-623
LID - 10.1080/14740338.2020.1718103 [doi]
AB  - Objectives: To assess the risk of adverse events (AEs) associated with 
      brentuximab vedotin in lymphoma patients.Methods: Articles were retrieved from 
      PubMed, Cochrane, and Clinicaltrials Databases to identify randomized controlled 
      trials (RCTs) comparing brentuximab vedotin with non-brentuximab vedotin in 
      lymphoma patients.Results: A total of 2225 patients from 4 RCTs were included. 
      Compared with the non-brentuximab vedotin group, the brentuximab vedotin group 
      significantly increased the risk of all-grade AEs (RR 1.05, 95% CI: 1.00-1.10), 
      and high-grade AEs (risk ratio [RR] 1.27, 95% confidence intervals [CI]: 
      1.01-1.58). The brentuximab vedotin group significantly increased the risk of 
      all-grade peripheral sensory neuropathy (RR 2.29, 95% CI: 1.23-4.26), pyrexia (RR 
      1.23, 95% CI: 1.05-1.44), nausea (RR 1.51, 95% CI: 1.05-2.18), vomiting (RR 1.54, 
      95% CI: 1.08-2.19), diarrhea (RR 1.69, 95% CI: 1.44-1.98), and alopecia (RR 1.18, 
      95% CI: 1.00-1.39), respectively. The brentuximab vedotin group significantly 
      increased the risk of high-grade sensory neuropathy (RR 4.79, 95% CI: 
      1.46-15.75), neutropenia (RR 1.48, 95% CI: 1.01-2.18), nausea (RR 2.65, 95% CI: 
      1.37-5.12), vomiting (RR 2.2, 95% CI: 1.17-4.12), and diarrhea (RR 1.85, 95% CI: 
      1.21-2.85).Conclusion: Brentuximab vedotin increased the risk of certain AEs in 
      lymphoma patients.
FAU - Gao, Siyuan
AU  - Gao S
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene 
      Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 
      China.
AD  - Department of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 
      Guangzhou, China.
FAU - Zhang, Mei
AU  - Zhang M
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene 
      Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 
      China.
AD  - Department of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 
      Guangzhou, China.
FAU - Wu, Kaishan
AU  - Wu K
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene 
      Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 
      China.
AD  - Department of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 
      Guangzhou, China.
FAU - Zhu, Jianhong
AU  - Zhu J
AUID- ORCID: 0000-0002-8320-891X
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene 
      Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 
      China.
AD  - Department of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 
      Guangzhou, China.
FAU - He, Zhichao
AU  - He Z
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene 
      Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 
      China.
AD  - Department of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 
      Guangzhou, China.
FAU - Li, Jianfang
AU  - Li J
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene 
      Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 
      China.
AD  - Department of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 
      Guangzhou, China.
FAU - Chen, Chuxiong
AU  - Chen C
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene 
      Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 
      China.
AD  - Department of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 
      Guangzhou, China.
FAU - Qiu, Kaifeng
AU  - Qiu K
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene 
      Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 
      China.
AD  - Department of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 
      Guangzhou, China.
FAU - Yu, Xiaoxia
AU  - Yu X
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene 
      Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 
      China.
AD  - Department of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 
      Guangzhou, China.
FAU - Wu, Junyan
AU  - Wu J
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene 
      Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 
      China.
AD  - Department of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 
      Guangzhou, China.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20200124
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 7XL5ISS668 (Brentuximab Vedotin)
SB  - IM
MH  - Antineoplastic Agents, Immunological/*administration & dosage/adverse effects
MH  - Brentuximab Vedotin/*administration & dosage/adverse effects
MH  - Humans
MH  - Lymphoma/*drug therapy/pathology
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - Brentuximab vedotin
OT  - adverse event
OT  - lymphoma patients
OT  - meta-analysis
EDAT- 2020/01/21 06:00
MHDA- 2021/01/22 06:00
CRDT- 2020/01/21 06:00
PHST- 2020/01/21 06:00 [pubmed]
PHST- 2021/01/22 06:00 [medline]
PHST- 2020/01/21 06:00 [entrez]
AID - 10.1080/14740338.2020.1718103 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2020 May;19(5):617-623. doi: 10.1080/14740338.2020.1718103. 
      Epub 2020 Jan 24.